Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues
- PMID: 20085605
- DOI: 10.1111/j.1469-0691.2009.03116.x
Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues
Abstract
Acquired carbapenemases are emerging resistance determinants in Gram-negative pathogens, including Enterobacteriaceae, Pseudomonas aeruginosa and other Gram-negative non-fermenters. A consistent number of acquired carbapenemases have been identified during the past few years, belonging to either molecular class B (metallo-beta-lactamases) or molecular classes A and D (serine carbapenemases), and genes encoding these enzymes are associated with mobile genetic elements that allow their rapid dissemination in the clinical setting. Therefore, detection and surveillance of carbapenemase-producing organisms have become matters of major importance for the selection of appropriate therapeutic schemes and the implementation of infection control measures. As carbapenemase production cannot be simply inferred from the resistance profile, criteria must be established for which isolates should be suspected and screened for carbapenemase production, and for which tests (phenotypic and/or genotypic) should be adopted for confirmation of the resistance mechanism. Moreover, strategies should be devised for surveillance of carbapenemase producers in order to enable the implementation of effective surveillance programmes. The above issues are addressed in this article, as a follow-up to an expert meeting on acquired carbapenemases that was recently organized by the ESCMID Study Group for Antibiotic Resistance Surveillance.
Comment on
-
The emerging threat of acquired carbapenemases in Gram-negative bacteria.Clin Microbiol Infect. 2010 Feb;16(2):99-101. doi: 10.1111/j.1469-0691.2009.03114.x. Clin Microbiol Infect. 2010. PMID: 20085603 No abstract available.
Similar articles
-
A convenient microbiological assay employing cell-free extracts for the rapid characterization of Gram-negative carbapenemase producers.J Antimicrob Chemother. 2008 Aug;62(2):336-44. doi: 10.1093/jac/dkn185. Epub 2008 May 2. J Antimicrob Chemother. 2008. PMID: 18456651
-
Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).Diagn Microbiol Infect Dis. 2007 Dec;59(4):425-32. doi: 10.1016/j.diagmicrobio.2007.05.009. Epub 2007 Jul 26. Diagn Microbiol Infect Dis. 2007. PMID: 17662557
-
[Broad-spectrum beta-lactamases in Gram-negative bacteria].Tidsskr Nor Laegeforen. 2008 Dec 4;128(23):2741-5. Tidsskr Nor Laegeforen. 2008. PMID: 19079424 Review. Norwegian.
-
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues.Int J Antimicrob Agents. 2007 Apr;29(4):380-8. doi: 10.1016/j.ijantimicag.2006.10.008. Epub 2007 Jan 16. Int J Antimicrob Agents. 2007. PMID: 17223319
-
Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.Clin Microbiol Infect. 2010 Feb;16(2):102-11. doi: 10.1111/j.1469-0691.2009.03115.x. Clin Microbiol Infect. 2010. PMID: 20085604 Review.
Cited by
-
Antibiotic resistance pattern and evaluation of metallo-beta lactamase genes (VIM and IMP) in Pseudomonas aeruginosa strains producing MBL enzyme, isolated from patients with secondary immunodeficiency.Adv Biomed Res. 2016 Jul 29;5:124. doi: 10.4103/2277-9175.186986. eCollection 2016. Adv Biomed Res. 2016. PMID: 27563634 Free PMC article.
-
Characterization of KPC-Producing Serratia marcescens in an Intensive Care Unit of a Brazilian Tertiary Hospital.Front Microbiol. 2020 May 20;11:956. doi: 10.3389/fmicb.2020.00956. eCollection 2020. Front Microbiol. 2020. PMID: 32670210 Free PMC article.
-
Purification and biochemical characterization of IMP-13 metallo-beta-lactamase.Antimicrob Agents Chemother. 2011 Jan;55(1):399-401. doi: 10.1128/AAC.00421-10. Epub 2010 Oct 25. Antimicrob Agents Chemother. 2011. PMID: 20974864 Free PMC article.
-
New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia.Ann Transl Med. 2018 Nov;6(21):423. doi: 10.21037/atm.2018.10.29. Ann Transl Med. 2018. PMID: 30581831 Free PMC article. Review.
-
Bacteriophage-Antibiotic Combination Therapy against Pseudomonas aeruginosa.Antibiotics (Basel). 2023 Jun 22;12(7):1089. doi: 10.3390/antibiotics12071089. Antibiotics (Basel). 2023. PMID: 37508185 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous